{"id":12244,"date":"2024-11-07T15:38:19","date_gmt":"2024-11-07T14:38:19","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=12244"},"modified":"2026-03-03T10:31:47","modified_gmt":"2026-03-03T09:31:47","slug":"blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/","title":{"rendered":"S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux!"},"content":{"rendered":"\n<p class=\"is-style-paragraph-lead-text\"><em>Une \u00e9quipe de recherche bas\u00e9e \u00e0 Hubrecht, aux Pays-Bas, a mis au point un nouveau mod\u00e8le d\u2019organo\u00efde h\u00e9patique reproduisant de mani\u00e8re tr\u00e8s fid\u00e8le le foie humain. Cette innovation offre une alternative prometteuse aux mod\u00e8les animaux et pourrait fournir une m\u00e9thode de s\u00e9lection plus rapide et plus efficace des traitements m\u00e9dicamenteux potentiels.<\/em><\/p>\n\n\n\n<p>La st\u00e9atose h\u00e9patique non alcoolique touche plus de 25% de la population mondiale, il existe toutefois peu de traitements efficaces. Jusqu\u2019ici, la plupart des recherches \u00e9taient bas\u00e9es sur des mod\u00e8les de rongeurs, qui ne reproduisent souvent pas fid\u00e8lement la biologie humaine. Les cellules h\u00e9patiques humaines cultiv\u00e9es en laboratoire se sont \u00e9galement r\u00e9v\u00e9l\u00e9es inadapt\u00e9es \u00e0 des essais cliniques \u00e0 grande \u00e9chelle. Cependant, des chercheurs ont d\u00e9sormais mis au point un mod\u00e8le d\u2019organo\u00efde r\u00e9volutionnaire utilisant des mini-foies (organo\u00efdes) cultiv\u00e9s \u00e0 partir de cellules h\u00e9patiques f\u0153tales humaines. Ces <strong>organo\u00efdes reproduisent tr\u00e8s fid\u00e8lement la fonction h\u00e9patique humaine r\u00e9elle.<\/strong><\/p>\n\n\n\n<p>\u00c0 l\u2019aide d\u2019outils g\u00e9n\u00e9tiques de pointe, les chercheurs ont pu recr\u00e9er les premiers stades de la st\u00e9atose h\u00e9patique non alcoolique dans ces organo\u00efdes, ce qui leur a permis de tester de nouveaux m\u00e9dicaments. Apr\u00e8s avoir \u00e9valu\u00e9 17&nbsp;m\u00e9dicaments, ils en ont identifi\u00e9&nbsp;5 qui r\u00e9duisaient l\u2019accumulation de graisse dans les cellules h\u00e9patiques. Il important de souligner que les diff\u00e9rences g\u00e9n\u00e9tiques dans les organo\u00efdes ont influenc\u00e9 l\u2019efficacit\u00e9 des m\u00e9dicaments. Les chercheurs ont \u00e9galement d\u00e9couvert un g\u00e8ne appel\u00e9 FADS2, qui pourrait jouer un r\u00f4le cl\u00e9 dans la r\u00e9duction des graisses h\u00e9patiques.<\/p>\n\n\n\n<p>&nbsp;L\u2019un des avantages du nouveau mod\u00e8le d\u2019organo\u00efde est qu\u2019il peut \u00eatre cultiv\u00e9 ind\u00e9finiment, ce qui le rend id\u00e9al pour tester des m\u00e9dicaments. Il fournit des r\u00e9sultats plus pr\u00e9cis que les mod\u00e8les animaux traditionnels, qui ne se transposent pas toujours bien aux humains. De plus, ce mod\u00e8le s\u2019aligne sur le principe des 3R, \u00e0 savoir la r\u00e9duction, le raffinement et le remplacement des exp\u00e9riences sur les animaux. Le chercheur principal, le professeur Hans Clevers, a soulign\u00e9 l\u2019importance de cette avanc\u00e9e, soulignant qu\u2019elle <strong>offre un moyen plus fiable de d\u00e9couvrir de nouveaux traitements et pourrait \u00eatre \u00e9tendue \u00e0 l\u2019\u00e9tude d\u2019autres maladies<\/strong>. Avec l\u2019int\u00e9r\u00eat d\u2019entreprises pharmaceutiques comme Roche, cette recherche pourrait avoir un impact significatif sur la d\u00e9couverte de m\u00e9dicaments et les tests d\u2019innocuit\u00e9.<\/p>\n\n\n\n<p>Auteurs: Christopher Cederroth, Jessica Lampe &amp; Robbie I\u2019Anson Price, Swiss 3R Competence Centre<\/p>\n\n\n\n<p><strong>R\u00e9f\u00e9rence:<\/strong> Hendricks D. et al. (2023) Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis. (\u00abDes organo\u00efdes d\u2019h\u00e9patocytes humains fabriqu\u00e9s permettant la d\u00e9couverte de cibles bas\u00e9es sur CRISPR et le criblage de m\u00e9dicaments contre la st\u00e9atose.\u00bb). Nat Biotechnol. 41, pages 1567 \u00e0 1581. <a href=\"https:\/\/doi.org\/10.1038\/s41587-023-01680-4\">https:\/\/doi.org\/10.1038\/s41587-023-01680-4<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Une \u00e9quipe de recherche bas\u00e9e \u00e0 Hubrecht, aux Pays-Bas, a mis au point un nouveau mod\u00e8le d\u2019organo\u00efde h\u00e9patique reproduisant de mani\u00e8re tr\u00e8s fid\u00e8le le foie humain. Cette innovation offre une alternative prometteuse aux mod\u00e8les animaux et pourrait fournir une m\u00e9thode de s\u00e9lection plus rapide et plus efficace des traitements m\u00e9dicamenteux potentiels. La st\u00e9atose h\u00e9patique non [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3354,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[],"class_list":["post-12244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux! - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux!\" \/>\n<meta property=\"og:description\" content=\"Une \u00e9quipe de recherche bas\u00e9e \u00e0 Hubrecht, aux Pays-Bas, a mis au point un nouveau mod\u00e8le d\u2019organo\u00efde h\u00e9patique reproduisant de mani\u00e8re tr\u00e8s fid\u00e8le le foie humain. Cette innovation offre une alternative prometteuse aux mod\u00e8les animaux et pourrait fournir une m\u00e9thode de s\u00e9lection plus rapide et plus efficace des traitements m\u00e9dicamenteux potentiels. La st\u00e9atose h\u00e9patique non [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-07T14:38:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T09:31:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2024\/11\/BIld-Artikel-9-Liver_organoid-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux!\",\"datePublished\":\"2024-11-07T14:38:19+00:00\",\"dateModified\":\"2026-03-03T09:31:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/\"},\"wordCount\":548,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2024\/11\/BIld-Artikel-9-Liver_organoid-scaled.jpg\",\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/\",\"name\":\"S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux! - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2024\/11\/BIld-Artikel-9-Liver_organoid-scaled.jpg\",\"datePublished\":\"2024-11-07T14:38:19+00:00\",\"dateModified\":\"2026-03-03T09:31:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2024\/11\/BIld-Artikel-9-Liver_organoid-scaled.jpg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2024\/11\/BIld-Artikel-9-Liver_organoid-scaled.jpg\",\"width\":2560,\"height\":2560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux! - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/","og_locale":"fr_FR","og_type":"article","og_title":"S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux!","og_description":"Une \u00e9quipe de recherche bas\u00e9e \u00e0 Hubrecht, aux Pays-Bas, a mis au point un nouveau mod\u00e8le d\u2019organo\u00efde h\u00e9patique reproduisant de mani\u00e8re tr\u00e8s fid\u00e8le le foie humain. Cette innovation offre une alternative prometteuse aux mod\u00e8les animaux et pourrait fournir une m\u00e9thode de s\u00e9lection plus rapide et plus efficace des traitements m\u00e9dicamenteux potentiels. La st\u00e9atose h\u00e9patique non [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/","og_site_name":"Interpharma","article_published_time":"2024-11-07T14:38:19+00:00","article_modified_time":"2026-03-03T09:31:47+00:00","og_image":[{"width":2560,"height":2560,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2024\/11\/BIld-Artikel-9-Liver_organoid-scaled.jpg","type":"image\/jpeg"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux!","datePublished":"2024-11-07T14:38:19+00:00","dateModified":"2026-03-03T09:31:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/"},"wordCount":548,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2024\/11\/BIld-Artikel-9-Liver_organoid-scaled.jpg","inLanguage":"fr-FR","copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/","name":"S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux! - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2024\/11\/BIld-Artikel-9-Liver_organoid-scaled.jpg","datePublished":"2024-11-07T14:38:19+00:00","dateModified":"2026-03-03T09:31:47+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2024\/11\/BIld-Artikel-9-Liver_organoid-scaled.jpg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2024\/11\/BIld-Artikel-9-Liver_organoid-scaled.jpg","width":2560,"height":2560},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/blogserie-mit-dem-3rcc-teil-9-neue-therapien-im-fokus-wie-bahnbrechende-tierversuchsfreie-forschung-den-weg-zur-behandlung-der-fettleber-ebnet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"S\u00e9rie de blogs en collaboration avec le 3RCC Partie 9:\u00a0Acc\u00e9der \u00e0 de nouvelles th\u00e9rapies: comment la recherche de pointe ouvre la voie aux traitements de la st\u00e9atose h\u00e9patique, sans recours aux animaux!"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=12244"}],"version-history":[{"count":1,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12244\/revisions"}],"predecessor-version":[{"id":12245,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12244\/revisions\/12245"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/3354"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=12244"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=12244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}